莫西沙星治疗老年重症肺炎的临床体会

Clinical experience of moxifloxacin in the treatment of elderly patients with severe pneumonia

目的探讨莫西沙星治疗老年重症肺炎的临床效果。方法选择56例老年重症肺炎患者,随机分为两组,对照组予头孢哌酮/舒巴坦钠针,观察组予莫西沙星针抗感染治疗。结果观察组治疗有效率为85.71%(24/28),对照组为78.57%(22/28),两组有效率比较无统计学差异(P>0.05);观察组在症状体征好转时间、退热时间及白细胞下降时间均明显短于对照组,P<0.05;治疗后观察组细菌清除率为81.25%(13/16),对照组为73.33%(11/15),两组P>0.05。结论莫西沙星治疗老年重症肺炎具有有效、快速、副作用少的特点。

Objective To investigate the clinical effect and security of moxifloxacin in the treatment of elderly patients with severe pneumonia. Methods 56 elderly patients with severe pneumonia were randomly divided into two groups. The control group was treated with cefoperazone/sulbactam sodium, and the observation group was treated with moxifloxacin. Results The effective rate was 85.71% （24/28） in the observation group, and 78.57% （22/28） in the control group, without significant difference （P 〉0. 05）. The time of improvement in signs and symptoms, fever and lcueopenia was significantly shorter in the observation group than in the control group, and the difference was statistically significant （P 〈 0. 05 ）. After the treatment, the clearance rate of bacterial was 81.25% （13/16） in the observation group, and 73.33% （11/15） in the control group （P 〉 0. 05 ）. Conclusion Moxifloxacin has the advantages of effective- ness, quickness, and fewer side reactions in the treatment of elderly patients with severe pneumonia.